STRO-004, a Next-Generation Tissue Factor (TF)-Targeted DAR8-Exatecan ADC, Demonstrates Superior Efficacy Across TF-Expressing Solid Tumors in a Comprehensive Single-Mouse PDX Trial

Presenter: Genevive Hernandez, Ph.D.

Phase 1 open-label study to evaluate safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004 in adults with refractory/recurrent metastatic solid tumors

Presenter: Jennifer Oliver, MD

STRO-006: An Integrin beta-6–targeting ADC demonstrates favorable safety profile and potent antitumor activity in preclinical solid tumors

Presenter: Kshama Doshi, Ph.D.

Preclinical characterization of STRO-227: A PTK7-targeting dual-payload ADC with topoisomerase 1 and tubulin inhibitors

Presenter: Daniel Calarese, Ph.D.

The HER2-targeting dual-payload antibody-drug conjugate combining a topoisomerase I inhibitor and a microtubule inhibitor demonstrates superior efficacy and overcomes resistance to single-payload ADCs in xenograft models

Presenter: Angela Matcham, Ph.D.

Sutro’s Site-Specific Dual-Payload ADCs Combining TOPO1i and DNA Damage Response Inhibitors to Enhance Efficacy, Overcome Resistance, and Improve Safety

Presenter: Krishna Bajjuri, Ph.D.